Pfiz­er, like Mod­er­na, fires back at Al­ny­lam suit over Covid-19 vac­cine patents

In the lat­est de­vel­op­ment over al­leged patent in­fringe­ment re­lat­ed to Pfiz­er’s and Mod­er­na’s mR­NA vac­cines for Covid-19, Pfiz­er is step­ping up to the plate and shar­ing its side of the sto­ry.

RNAi ther­a­peu­tics gi­ant Al­ny­lam knew be­fore it filed its orig­i­nal suit that Pfiz­er’s Covid vac­cine Comir­naty did not vi­o­late Al­ny­lam’s patent, Pfiz­er wrote in its 37-page re­sponse filed late last week in Delaware dis­trict court in re­sponse to Al­ny­lam’s suit. Al­ny­lam had al­leged patent in­fringe­ment and de­mand­ed mon­e­tary com­pen­sa­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER